Hemophilia Treatment Market Size to Exceed USD 26,405.1 Mn by 2032

The Hemophilia Treatment Market, estimated at USD 17,182.9 Mn in 2025, is expected to exhibit a CAGR of 6.33% and reach USD 26,405.1 Mn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Increasing adoption of growth strategies such as merger and acquisition of companies by key market player is expected to drive the global hemophilia treatment market growth over the forecast period. For instance, in February 2025, Spark Therapeutics, a developer of gene therapy treatments, announced it had entered into a definitive merger agreement with Roche, a multinational healthcare company, to aquire Spark Therapeutics in order to expand the development of gene therapies for patients.

Global Hemophilia Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdowns in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.

However, the COVID-19 pandemic had a negative impact on the global hemophilia treatment market. For instance, in April 2025, Kedrion Biopharma and Kamada, a biopharmaceutical company, forged ahead with the development of a new Anti-COVID Immunoglobulin therapy derived from the plasma of convalescent patients.

Global Hemophilia Treatment Market: Key Developments

In November 2025, Enzyre, a developing breakthrough ambulant diagnostic technology for blood coagulation testing, announced it had successfully raised US$ 12 million in a Series A financing led by new investor, Oost NL, with participation from i&i Biotech Fund, Demcon Investment as a technology partner and existing investors, Takeda Ventures and Novalis Biotech.

In October 2025, The Australian Hemophilia Center Directors’ Organisation (AHCDO) developed the gene therapy Roadmap to provide a clinical implementation Plan that sets out AHCDO’s position on the preferred approach of implementation of gene therapy for hemophilia in Australia.

Browse 35 Market Data Tables and 34 Figures spread through 180 Pages and in-depth TOC on “Global Hemophilia Treatment Market”- Forecast to 2032, Global Hemophilia Treatment Market, By Product Type (Plasma Derived Coagulation Factor, Recombinant Coagulation Factor , Antifibrinolytic Agents, and Desmopressin), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Link:

Furthermore, key players are looking forward to adopt inorganic strategies, such as collaborations to develop novel therapies for hemophilia treatment, and this is expected to fuel growth of the hemophilia treatment market. For instance, in July 2025, Sangamo Therapeutics, Inc., a genomic medicine company, and Pfizer,Inc., pharmaceutical and biotechnological corporation, announced the updated results from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A.

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/hemophilia-treatment-market-2012

Key Takeaways of the Global Hemophilia Treatment Market:

Global hemophilia treatment market is expected to exhibit a CAGR of 6.33% during the forecast period, owing to rising incidence of hemophilia and approvals and launches of novel products. For instance, according to centers for Disease Control and Prevention (CDC) hemophilia occurs in approximately 1 out of 5,617 live male births. There are between 30,000-33,000 males with hemophilia in the U.S.
Among product type, plasma derived coagulation factor is estimated to hold a dominant position in the global hemophilia treatment market, due to increasing disease awareness and hence key players are indulged in inorganic strategies such as acquisition. For instance, in September 2025, Novo Nordisk, a pharmaceutical company, and Forma therapeutics, a biopharmaceutical company, announced both companies had entered into a definitive agreement. This acquisition will include Forma therapeutics’s lead development candidate, etavopivat, is aligned with Novo Nordisk’s strategy to complement and accelerate its scientific presence and pipeline in haemoglobinopathies, a group of disorders in which there is abnormal production.
Among region, Asia Pacific is fastest growing region during the forecast period in the global hemophilia treatment market, as market key players are committed to to advanced personalized care in people living with hemophilia and this is expected to drive the market growth over the forecast period. For Instance, in July 2025, Takeda Pharmaceutical Company announced that 13 abstracts from the company’s Hematology portfolio, and pipeline for hemophilia treatment are presented at the International Society on Thrombosis and Haemostasis 2025 Virtual Congress (ISTH 2025). The data demonstrated benefits of pharmacokinetic-guided prophylaxis therapy in Hemophilia.
Major players operating in the global hemophilia treatment market include Takeda Pharmaceutical Co., Ltd., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, and F. Hoffmann-La Roche AG.